Key result
DOAC levels fall outside the reference range in ~20% of cancer patients undergoing chemotherapy.
Why the study?
Do cancer patients undergoing chemotherapy maintain therapeutic plasma concentrations of direct oral anticoagulants?
Observational (n=17)
No
Do cancer patients undergoing chemotherapy maintain therapeutic plasma concentrations of direct oral anticoagulants?
Routine monitoring of DOAC plasma concentrations may be warranted in cancer patients undergoing chemotherapy, as approximately 20% exhibit non-therapeutic levels, particularly those receiving hormone therapy for prostate cancer.
May support DOAC monitoring during chemotherapy; leaves open impact on clinical outcomes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Sławiński et al. (2026) conducted an observational in Active cancer undergoing chemotherapy and on DOACs (n=17). Direct oral anticoagulants (dabigatran, apixaban, rivaroxaban) was evaluated on DOAC plasma concentrations outside the reference range.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: